The product is a recombinant human coagulation Factor Xa that promotes blood coagulation. The product works by binding to Factor Xa inhibitors and prevent them from interacting with endogenous Factor Xa. The product retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation pathways and remains catalytically inactive due to structural modification. The procoagulation potential of the product is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, it is unable to bind to membrane surfaces and assemble the prothrombinase complex. It also prevents the product from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex. The amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters it from converting prothrombin to thrombin. rfXa Inhibitor Antidote https://www.creativebiomart.net/therapeutic-proteins/p/48/recombinant-human-coagulation-factor-xa/
The product is a recombinant human coagulation Factor Xa that promotes blood coagulation. The product works by binding to Factor Xa inhibitors and prevent them from interacting with endogenous Factor Xa. The product retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation pathways and remains catalytically inactive due to structural modification. The procoagulation potential of the product is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, it is unable to bind to membrane surfaces and assemble the prothrombinase complex. It also prevents the product from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex. The amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters it from converting prothrombin to thrombin. rfXa Inhibitor Antidote https://www.creativebiomart.net/therapeutic-proteins/p/48/recombinant-human-coagulation-factor-xa/
WWW.CREATIVEBIOMART.NET
Andexanet alfa, Recombinant human coagulation Factor Xa - Therapeutic Proteins
The product is a recombinant human coagulation Factor Xa that promotes blood coagulation. The product works by binding to Factor Xa inhibitors and prevent them from interacting with endogenous Factor Xa. The product retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation pathways and remains catalytically inactive due to structural modification. The procoagulation potential of the product is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, it is unable to bind to membrane surfaces and assemble the prothrombinase complex. It also prevents the product from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex. The amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters it from converting prothrombin to thrombin.
0 Комментарии 0 Поделились
Спонсоры